1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,300 | 5,350 | 13.06. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.06. | WUXI XDC (02268): FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 26, 2026 | - | HKEx | ||
| 01.06. | WUXI XDC (02268): NOTICE OF ANNUAL GENERAL MEETING | - | HKEx | ||
| 01.06. | WUXI XDC (02268): (1) PROPOSED RE-ELECTION OF RETIRING DIRECTORS (2) PROPOSED RE-APPOINTMENT OF AUDITORS (3) PROPOSED GRANT OF GENERAL MANDATES TO ISSUE ... | - | HKEx | ||
| 29.05. | WUXI XDC: Professional Trustee Buys 5.7M+ Shares Involving HKD327M | 1 | AASTOCKS | ||
| 29.05. | WUXI XDC (02268): VOLUNTARY ANNOUNCEMENT SHARE PURCHASE FOR THE SHARE SCHEMES OF THE COMPANY | 1 | HKEx | ||
| WUXI XDC Aktie jetzt für 0€ handeln | |||||
| 19.05. | WUXI XDC Opens 2.15% Higher w/Plan of Share Buyback of Up to USD100M | 1 | AASTOCKS | ||
| 18.05. | WUXI XDC (02268): VOLUNTARY ANNOUNCEMENT PROPOSED ON-MARKET SHARE PURCHASE FOR THE SHARE SCHEMES OF THE COMPANY | - | HKEx | ||
| 24.04. | WUXI XDC (02268): ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT 2025 | 1 | HKEx | ||
| 24.04. | WUXI XDC (02268): ANNUAL REPORT 2025 | - | HKEx | ||
| 09.04. | Akari Therapeutics Plc: Akari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDC | 4 | GlobeNewswire (USA) | ||
| 08.04. | WUXI XDC (02268): NEXT DAY DISCLOSURE RETURNS | - | HKEx | ||
| 08.04. | WUXI XDC (02268): GRANT OF RESTRICTED SHARES UNDER THE 2024 SHARE SCHEME | 1 | HKEx | ||
| 06.04. | Akari Therapeutics slides 21% despite WuXi XDC backing its drug program | 3 | Seeking Alpha | ||
| 06.04. | Akari Therapeutics Partners with WuXi XDC to Accelerate Development of Novel PH1 Payload | 1 | Contract Pharma | ||
| 06.04. | Akari Therapeutics partners with WuXi XDC on ADC development | 2 | Investing.com | ||
| 06.04. | Akari Therapeutics Plc: Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing | 178 | GlobeNewswire (Europe) | TAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing... ► Artikel lesen | |
| 31.03. | WUXI XDC (02268): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ALL ... | 2 | HKEx | ||
| 23.03. | WUXI XDC (02268): INSIDE INFORMATION 2025 ANNUAL RESULTS PRESENTATION | - | HKEx | ||
| 23.03. | WUXI XDC (02268): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2025 | 1 | HKEx | ||
| 13.03. | WUXI XDC (02268): JOINT ANNOUNCEMENT VOLUNTARY CONDITIONAL CASH OFFERS BY CITIGROUP GLOBAL MARKETS ASIA LIMITED FOR AND ON BEHALF OF THE OFFEROR FOR ALL ... | 8 | HKEx |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 88,33 | 0,00 % | Apogee Therapeutics, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 46,130 | 0,00 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| QIAGEN | 31,980 | -0,28 % | Qiagen-Aktie: Schlafender Riese und Übernahme-Kandidat? | Nach kurstechnisch harten Monaten kämpft sich die Aktie des niederländischen Biotechnologie- und Diagnostikunternehmens Qiagen langsam zurück. Mit Kursen um 32 Euro notiert das Papier noch immer mehr... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,000 | -0,07 % | Summit Therapeutics: CEO-Aktienkauf sorgt für Kursplus | ||
| IMMUNOME | 18,380 | 0,00 % | Immunome Inc. - 8-K, Current Report | ||
| TANGO THERAPEUTICS | 30,960 | +0,06 % | Starke Studiendaten: Nach 626% Kursplus in einem Jahr: Dieser Krebsspezialist macht Anleger sprachlos | © Foto: Bernd Weißbrod/dpa Ein Wirkstoff gegen die tödlichste Form von Bauchspeicheldrüsenkrebs zeigt Daten, die selbst erfahrene Onkologen aufhorchen lassen. Die Aktie reagierte entsprechend.Pankreas-Karzinom... ► Artikel lesen | |
| MBX BIOSCIENCES | 35,510 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism | Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail trial Results consistent with restoration of systemic PTH activity through serum calcium... ► Artikel lesen | |
| IMMUNOVANT | 33,620 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 267,07 | +0,18 % | Praxis Precision Medicines, Inc. - 8-K, Current Report | ||
| ADMA BIOLOGICS | 8,210 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics Stock Alert (ADMA) - Kehoe Law Firm, P.C. Investigating Potential Securities Claims on Behalf of ADMA Biologics Investors | Philadelphia, Pennsylvania--(Newsfile Corp. - May 7, 2026) - Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of ADMA Biologics, Inc. ("ADMA Biologics" or... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 34,830 | 0,00 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| ALUMIS | 24,170 | +0,08 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| COGENT BIOSCIENCES | 33,080 | -0,06 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress | - JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - - Selective JAK V617F inhibitor, CGT1145... ► Artikel lesen | |
| NURIX THERAPEUTICS | 16,950 | 0,00 % | Biotech-Partnerschaft: Roche greift zu: Dieser Milliarden-Deal lässt Anleger aufhorchen | © Foto: Vladimir Borovic - Adobe StockRoche steigt mit einem milliardenschweren Deal bei Nurix ein. Im Fokus steht ein vielversprechender Wirkstoff gegen Krebs, Autoimmun- und Nervenkrankheiten.Der... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,590 | -0,13 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics to Present Late-Breaking Data on Lorundrostat at The Endocrine Society Annual Meeting (ENDO 2026) |
Das Unternehmen WUXI XDC CAYMAN INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +5,69 % bei einem Aktienkurs von 5,200 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu WUXI XDC CAYMAN INC finden Sie auf Wallstreet Online.